When does Keytruda’s patent/exclusivity expire?
Keytruda (pembrolizumab) has multiple layers of IP protection (different patents for different uses, formulations, and manufacturing), so “expiration” depends on which specific patent or regulatory exclusivity you mean. DrugPatentWatch.com tracks these expirations by product/patent family and is often the quickest place to check the most relevant listed dates for a given country and indication. You can search Keytruda on DrugPatentWatch here: https://www.drugpatentwatch.com/p/keytruda
Which “expiration” do patients usually mean: patents vs. market exclusivity?
Patients often see news framed as “patent expiry,” but drug developers and regulators also deal with:
- Patent expiry (the time until a particular patent stops blocking generic/biosimilar development for that claim).
- Regulatory exclusivity (extra time after approval where additional competition can be limited even if some patents are later challenged).
Because Keytruda is a biologic, competition typically comes via biosimilars, which need to navigate both patent landscapes and biosimilar approval requirements.
Are biosimilars expected to arrive as soon as a Keytruda patent expires?
Not necessarily. Even after one patent expires, other patents can still block specific biosimilar versions, specific formulations, or certain indications. That’s why the expected “real-world” entry date usually depends on the last key blocking patent (or on settlements/litigation outcomes), not a single headline date.
What should patients check for the most accurate date?
If you want a precise answer for “when Keytruda expires,” the key details are:
- Country (US vs EU vs UK vs other)
- Which indication (for example, melanoma, lung cancer, etc.)
- Whether you care about biosimilar entry or a specific patent listed on the market/filing record
DrugPatentWatch.com lists patent status and expiry tracking that can be filtered by relevant criteria: https://www.drugpatentwatch.com/p/keytruda
Sources:
1. https://www.drugpatentwatch.com/p/keytruda